Theralase Technologies Inc. (TLTFF)

Market Cap	42.73M +20.0%
Revenue (ttm)	565.07K -24.9%
Net Income	-2.67M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	108,000
Open	0.1342
Previous Close	0.1300
Day's Range	0.1305 - 0.1400
52-Week Range	0.1019 - 0.3061
Beta	0.56
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 27, 2026

About Theralase Technologies

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of energy activated small molecules and associated drug formulations in Canada, the United States, and internationally. The company operates in two segments, Drug Division and Device Division. It engages in the research and development of Rutherrin, an injectable form of Ruvidar for the treatment of glio blastoma multiforme, a form of brain cancer, non-small cell lung cancer, pancreatic cancer, colorectal cancer, and...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: Roger Dumoulin-White
• Employees: 20
• Stock Exchange: OTCMKTS
• Ticker Symbol: TLTFF

Financial Performance

In 2025, Theralase Technologies's revenue was 816,468, a decrease of -20.99% compared to the previous year's 1.03 million. Losses were -4.12 million, -3.18% less than in 2024.

Financial numbers in CAD

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 10, 2026

Data Sources Report a data error